| 0 (0%) | 12-27 00:24 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.71 | 1-year : | 7.83 |
| Resists | First : | 5.74 | Second : | 6.71 |
| Pivot price | 4.93 |
|||
| Supports | First : | 4.62 | Second : | 3.94 |
| MAs | MA(5) : | 5.22 |
MA(20) : | 4.96 |
| MA(100) : | 5.24 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 70.5 |
D(3) : | 71.6 |
| RSI | RSI(14): 54.2 |
|||
| 52-week | High : | 7.19 | Low : | 1.13 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ALDX ] has closed below upper band by 25.4%. Bollinger Bands are 68.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.33 - 5.35 | 5.35 - 5.37 |
| Low: | 5.05 - 5.07 | 5.07 - 5.09 |
| Close: | 5.27 - 5.31 | 5.31 - 5.35 |
Wed, 24 Dec 2025
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Above Fifty Day Moving Average - Should You Sell? - MarketBeat
Thu, 18 Dec 2025
ALDX LEGAL NEWS: BFA Law Announces that Aldeyra Therapeutics, Inc. is being Investigated - Contact the Firm if You Lost Money - 28/22 News
Tue, 16 Dec 2025
Why Is Aldeyra Therapeutics Stock Falling Tuesday? - Aldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
Tue, 16 Dec 2025
Aldeyra Therapeutics (ALDX) Faces FDA Review Delay for Reproxala - GuruFocus
Tue, 16 Dec 2025
Biotech Stocks Today: FDA Fast Track Wins, PDUFA Delays and Deal Flow Move GLUE, ALDX, ADAG, PVLA as XBI and IBB Slide - ts2.tech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 60 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 66.2 (%) |
| Shares Short | 5,870 (K) |
| Shares Short P.Month | 5,300 (K) |
| EPS | -0.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.81 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29 % |
| Return on Equity (ttm) | -64.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -40 (M) |
| Levered Free Cash Flow | 16 (M) |
| PE Ratio | -7.28 |
| PEG Ratio | 0 |
| Price to Book value | 6.47 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|